Shanghai RAAS Blood Products Co., Ltd. (SHE: 002252)

Shanghai RAAS Blood Products Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	3,712	4,001	3,978	2,747	1,953	1,436
Trading Asset Securities	-	197.41	237.77	219.38	262.14	295.4
Cash & Short-Term Investments	3,712	4,199	4,216	2,966	2,215	1,732
Cash Growth	-12.37%	-0.40%	42.11%	33.90%	27.92%	45.40%
Accounts Receivable	1,377	774.08	915.44	649.52	580.2	862.08
Other Receivables	4.54	8.22	2.02	1.21	0.17	5.75
Receivables	1,382	782.3	917.46	650.73	580.37	867.82
Inventory	3,874	3,667	3,269	3,173	2,163	1,913
Prepaid Expenses	-	-	0.1	0.14	0.13	0.28
Other Current Assets	122.27	27.28	71.41	81.69	53.09	17.81
Total Current Assets	9,090	8,675	8,473	6,872	5,012	4,531
Property, Plant & Equipment	1,827	1,453	1,282	1,279	1,229	1,136
Long-Term Investments	15,146	16,177	15,702	13,878	13,678	360.43
Goodwill	5,073	5,073	4,703	4,900	5,261	5,391
Other Intangible Assets	492.63	233.85	175.49	163.18	172.42	183.79
Long-Term Deferred Tax Assets	79.8	89.81	83.55	104.27	96.35	173.41
Long-Term Deferred Charges	26.42	21.29	25.78	28.97	33.17	32.16
Other Long-Term Assets	1,627	205.34	13	11.54	11.71	45.65
Total Assets	33,363	31,928	30,458	27,237	25,494	11,853
Accounts Payable	1,624	1,643	1,130	956.29	87	52.72
Accrued Expenses	118.42	289.17	275.36	234.64	183.88	181.17
Short-Term Debt	-	-	-	-	7.74	-
Current Portion of Leases	1.55	0.41	1.98	4.09	-	-
Current Income Taxes Payable	77.6	94.57	91.03	53.53	7.8	21.6
Current Unearned Revenue	4.98	22.64	91.76	28.69	10.88	8.08
Other Current Liabilities	334.33	195.1	34.54	29.38	32.93	45.84
Total Current Liabilities	2,161	2,245	1,625	1,307	330.24	309.4
Long-Term Leases	0.01	1.49	1.85	4.16	-	-
Long-Term Unearned Revenue	8.61	9.49	12.77	15.2	25.31	40.41
Long-Term Deferred Tax Liabilities	15.13	16.02	5.34	6.44	8.19	12.13
Other Long-Term Liabilities	3.03	7.06	-	-	-	-
Total Liabilities	2,188	2,279	1,645	1,332	363.73	361.95
Common Stock	6,638	6,645	6,741	6,741	6,741	4,975
Additional Paid-In Capital	14,036	13,805	14,560	14,560	14,558	3,059
Retained Earnings	10,504	9,110	7,533	5,843	4,715	3,459
Treasury Stock	-120.4	-182.92	-	-	-	-
Comprehensive Income & Other	102.26	255.67	-15.72	-1,241	-891.49	-14.19
Total Common Equity	31,160	29,634	28,819	25,902	25,123	11,479
Minority Interest	14.67	15.86	-5.37	1.72	7.28	12.4
Shareholders' Equity	31,174	29,650	28,813	25,904	25,130	11,491
Total Liabilities & Equity	33,363	31,928	30,458	27,237	25,494	11,853
Total Debt	1.56	1.91	3.82	8.25	7.74	-
Net Cash (Debt)	3,711	4,197	4,212	2,958	2,208	1,732
Net Cash Growth	-12.36%	-0.36%	42.38%	34.00%	27.48%	66.35%
Net Cash Per Share	0.56	0.63	0.62	0.44	0.34	0.34
Filing Date Shares Outstanding	6,633	6,605	6,741	6,741	6,741	6,741
Total Common Shares Outstanding	6,633	6,605	6,741	6,741	6,741	4,975
Working Capital	6,929	6,431	6,849	5,566	4,682	4,222
Book Value Per Share	4.70	4.49	4.28	3.84	3.73	2.31
Tangible Book Value	25,594	24,327	23,940	20,839	19,689	5,904
Tangible Book Value Per Share	3.86	3.68	3.55	3.09	2.92	1.19
Buildings	-	1,343	1,195	1,146	1,016	937.91
Machinery	-	1,216	1,132	1,074	988.43	904.26
Construction In Progress	-	134.03	74.19	26.89	105.48	85.35

Source: S&P Capital IQ. Standard template. Financial Sources.